Five patients with thrombotic thrombocytopenic purpura (TTP) were treated with vincristine sulfate with reversal of all clinical and hematologic evidence of disease. In three patients, the diagnosis was confirmed by biopsy. Vincristine was the principal therapeutic agent in two patients. Remissions have been sustained without maintenance therapy for up to seven years. These observations suggest vincristine to be effective in the treatment of TTP.
Gutterman LA, Stevenson TD. Treatment of Thrombotic Thrombocytopenic Purpura With Vincristine. JAMA. 1982;247(10):1433–1436. doi:10.1001/jama.1982.03320350037025
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: